MANIFESTATION OF CLINICAL SYMPTOMS OF BLASTOCYSTOSIS AND EFFECTIVENESS OF ITS THERAPY

Introduction. The individualization of therapy for patients with blastocystosis primarily depends on the clinician's ability to predict the effectiveness of the chosen treatment tactics before the start of its implementation. The predictive properties of the clinical symptoms of patients are not excluded. Materials and methods. To determine whether there is a relationship between the clinical manifestations of blastocystosis and the effectiveness of its therapy, the data on clinical symptoms in 300 patients with blastocystosis in alternative groups were compared: group A – with a good therapeutic effect (n=162), and group B – with a satisfactory effect (n=138). Group A included patients who had a clinical symptom regression rate of ≥33% after 1 month of treatment, and group B - ≤ 32%. Results and discussion. The analysis revealed that in the group with effective therapy, compared with the alternative group, the following were significantly more often diagnosed: age of patients ≤ 20 years (2.3 times; p < 0.001); severe (≥ 11 points) total manifestation of the disease (1.9 times; p < 0.001); significant (≥ 3.1 years) duration of the disease (2.8 times; p < 0.001); reduction in the incidence of the disease (2.8 times; p < 0.001), as well as the presence of subfebrile temperature (1.8 times; p < 0.001); decreased performance throughout the day (2 times; p < 0.001); headache during exercise or at rest (1.4 times; p < 0.001); dizziness during exercise (2.7 times; p < 0.001); heaviness in the right hypochondrium (7.1 times; p < 0.001); severe muscle pain (1.9 times; p < 0.001); joint pain in both single joints (1.7 times; p < 0.001) and in a group of joints (2.7 times; p < 0.001); pain in the heart area (1.9 times; p < 0.05); tachycardia at rest (3,4 times; p < 0.001); hyperplasia of single lymph nodes (1.4 times; p < 0.001); moderate hepatomegaly (2 times; p < 0.001) and splenomegaly (1.7 times; p < 0.01); vegetative-visceral dysfunctions (1,5 times; p < 0.001). There were no significant differences between the groups in the manifestation of the following symptoms: memory impairment (p > 0.05), as well as the presence of dyspeptic syndrome and skin manifestations (p > 0.05). The greatest differences in the frequency of clinical symptoms in groups with different efficacy of therapy were found in the presence of: tachycardia at rest (3.4 times; p < 0.001); duration of the disease (2.8 times; p < 0.001); dizziness during exercise (2.7 times; p < 0.001) and pain in the joint group (2.7 times; p < 0.001). Conclusions. In patients with blastocystosis, a significant relationship between the nature of clinical symptoms and the effectiveness of therapy was found, which makes it possible to use them for prognostic purposes.